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Correlating Infant Fecal Microbiota Composition and
Human Milk Oligosaccharide Consumption by Microbiota
of 1-Month-Old Breastfed Infants
Klaudyna Borewicz,* Fangjie Gu, Edoardo Saccenti, Ilja C.W. Arts, John Penders,
Carel Thijs, Sander S. van Leeuwen, Cordula Lindner, Arjen Nauta, Ellen van Leusen,
Henk A. Schols, and Hauke Smidt*
Scope: Understanding the biological functions of human milk oligosaccharides (HMOs) in shaping gastrointestinal (GI)
tract microbiota during infancy is of great interest. A link between HMOs in maternal milk and infant fecal microbiota
composition is examined and the role of microbiota in degrading HMOs within the GI tract of healthy, breastfed, 1-
month-old infants is investigated.
Methods and results: Maternal breast milk and infant feces are from the KOALA Birth Cohort. HMOs are quantiﬁed in
milk and infant fecal samples using liquid chromatography-mass spectrometry. Fecal microbiota composition is charac-
terized using Illumina HiSeq 16S rRNA gene amplicon sequencing. The composition is associated with gender, delivery
mode, andmilkHMOs: Lacto-N-fucopentaose I and 2′-fucosyllactose. Overall,Bifidobacterium, Bacteroides, Escherichia–
Shigella, and Parabacteroides are predominating genera. Three diﬀerent patterns in infant fecal microbiota structure are
detected. GI degradation of HMOs is strongly associated with fecal microbiota composition, and there is a link between
utilization of speciﬁc HMOs and relative abundance of various phylotypes (operational taxonomic units).
Conclusions: HMOs in maternal milk are among the important factors shaping GI tract microbiota in 1-month-old
breastfed infants. An infant’s ability to metabolize diﬀerent HMOs strongly correlates with fecal microbiota composition
and speciﬁcally with phylotypes within genera Bifidobacterium, Bacteroides, and Lactobacillus.
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1. Introduction
During and after birth, microorganisms from the mother and
other environmental sources colonize an infant. Genetic and var-
ious environmental factors and life events further shape the mi-
crobial communities, making them speciﬁc to each body site and
to each individual. These microbial ecosystems acquired and de-
veloped in early life play an important role in well-being and
health, both during infancy and beyond.[1] One of the body sites
that undergoes a rapid microbial colonization in early life is
the gastrointestinal (GI) tract.[1] The anaerobic conditions in the
lower GI tract favor the establishment of bacteria, such as Bifi-
dobacterium, Bacteroides, and Clostridium.[1] Besides the absence
of oxygen, diet is another key factor that has a strong inﬂuence
on shaping the GI microbial ecosystem.
In breastfed infants, breast milk is the sole source of nour-
ishment during the ﬁrst few months of life. Breast milk is a
complex bioﬂuid that contains high concentrations of lactose,
lipids, proteins, and milk glycans, the latter being present
as either glycoproteins or free human milk oligosaccharides
(HMOs).[2] HMOs play an important role in intestinal cell prolif-
eration and maturation, maintaining epithelial barrier function,
and protecting the GI tract against bacterial and viral pathogens
and toxins.[2–5] Despite being the third most abundant compo-
nent of human milk, HMOs are not aﬀected by infant digestive
enzymes.[2] As a result, milk HMOs reach the infant colon,
where they are degraded by bacteria. Since not all bacteria have
the necessary enzymes to utilize HMOs, these milk glycans facil-
itate the establishment of a highly specialized microbial ecosys-
tem dominated by biﬁdobacteria and Bacteroides among others,
while indirectly limiting growth of other bacteria. This prebiotic
eﬀect has been demonstrated for selected bacterial species, both
in vitro[3,6] and in vivo,[7] and it has been recognized as one of
the key drivers for bacterial species succession in the infant GI
tract.[5]
Maternal genotype (e.g., mother’s secretor status) determines
the HMO composition in breast milk, and the concentrations
of diﬀerent HMOs vary between individuals and across lac-
tation stages.[8–10] This variability might target the distinct
and changing needs of a growing infant and orchestrate the
stepwise development of infant GI tract microbiota. Recent
developments in glycomics led to the recognition of over 200
diﬀerent HMOs in human milk.[2] The core structures of HMOs
include galactose, glucose, and N-acetyl-glucosamine, which are
further decorated with fucose and/or sialic acid. The fucosylation
of HMOs depends on the presence of speciﬁc glycosyltrans-
ferases, including the α1-2-fucosyltransferase FUT2 and the
α1-3/4-fucosyltransferase FUT3, in lactating women. Milk of
secretor women having active Se gene locus that encodes the
FUT2 has high amounts of α1-2-fucosylated HMOs, while milk
of Lewis-positive women with active Le gene locus that encodes
the FUT3 is abundant in α1-4-fucosylated HMO. In contrast,
milk of non-secretor or Lewis-negative women lack α1-2- or
α1-4-fucosylated HMO, respectively.[11] Based on the presence
or absence of sialic acid, HMOs can be classiﬁed into two
categories: the neutral and the acidic HMOs. In this study, we
measured 17 highly abundant HMOs, including 12 neutral and
5 acidic HMOs (Table S1, Supporting Information). The con-
centrations of these major HMO structures account for around
86% of the total HMOs in breast milk of secretors, 35 days
postpartum.[12]
In the light of growing evidence supporting the role of the
early colonization of GI tract microbial ecosystem in health,
understanding the biological function of the diﬀerent HMOs
is of great interest. Previous studies focused mainly on in vitro
fermentation of HMOs by fecal bacterial inoculum, or by fecal
isolates.[3] A proof-of concept study showed correlation between
HMO degradation and gut microbiota development in early life
by analyzing samples from two infants.[12] However, the HMO
degradation within an infant GI tract is still not fully understood.
Here, we analyzed 121 mother–infant pairs to investigate the as-
sociation between selected maternal HMOs and the infant fecal
microbiota composition. Our two main research questions were
i) whether there was an association between the composition of
HMOs in breast milk and the composition of fecal microbiota in
healthy, breastfed, 1-month-old infants, and ii) if the degradation
of these HMOs could be linked to infant fecal microbial com-
munities and to speciﬁc bacterial taxa found in the infant’s GI
tract.
2. Experimental Section
2.1. Milk and Fecal Sample Collection
The milk and fecal samples used in this study originated from
the KOALA Birth Cohort (Dutch acronym for Child, Parents and
Health: Lifestyle andGenetic Constitution). The design, selection
criteria, and feces collection procedure have been described else-
where, and the study was approved by the Ethics Committee of
the University Hospital of Maastricht.[13–15] Brieﬂy, the KOALA
study included healthy pregnant women living in the south of
the Netherlands (N = 2834), and the exclusion criteria included
prematurity (birth before 37 weeks of gestation), twins, congen-
ital abnormalities related to growth, and administration of an-
timicrobial agents before feces collection. Only infants who were
exclusively breastfed, and for whom both the fecal and the corre-
sponding maternal breast milk samples were available were in-
cluded in the analyses (n = 121). All infants were born in the
years 2002–2003, healthy, full term, at home or hospital via ei-
ther vaginal delivery or C-section. Three infants were reported by
the parents as sick on the sample collection day, but none of the
infants received antibiotics during the ﬁrst month of life (Tables
S1 and S2, Supporting Information). Infant fecal samples were
collected at approximately 1 month postpartum from infants’ di-
apers, refrigerated, and sent to the lab by post within 1 day after
collection. Fecal samples were stored in peptone glycerol solution
(10 g L−1 peptone water in 20 v/v% glycerol) at 1 g of feces in 9mL
of solution. Breast milk samples were collected into sterile tubes
(Cellstar PP-test tubes, Kremsmu¨nster, Austria) in the morning
on the same day as the fecal samples, refrigerated (±4 °C), trans-
ported on ice, and processed in the lab on the same day. Breast
milk samples were centrifuged (400 × g, 12 min, no brake, 4 °C)
and the lipid and aqueous fraction were separated and stored in
plastic vials (Sarstedt, Nu¨mbrecht, Germany) at−80 °C in the Eu-
ropean Biobank, Maastricht. The remaining debris was not used
to avoid contamination with cell fragments.
Mol. Nutr. Food Res. 2019, 1801214 1801214 (2 of 13) C© 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
www.advancedsciencenews.com www.mnf-journal.com
2.2. Dosage Information/Dosage Regime
The total amount of HMOs ingested daily by each infant de-
pended on the HMO concentration in breast milk and the total
amount of breast milk consumed per day. The daily intake was
estimated based on the literature data on infants of similar age
(approximately 1month postpartum)whowere breastfedwithout
feeding problems and consumed amounts as regulated according
to their needs.[16]
2.3. DNA Extraction , PCR and sequencing
Total DNA was extracted from the stool samples, as previously
described,[17] using the double bead-beating procedure followed
by the QIAamp DNA stool mini kit (Qiagen, Hilden, Germany)
according to themanufacturer’s instructions. The resulting DNA
templates (5–20 ng) were used for subsequent PCR ampliﬁcation
and Illumina HiSeq sequencing of the V4 region of 16S riboso-
mal RNA (rRNA) genes.[18]
2.4. HMO Analysis
HMOs were isolated and puriﬁed from milk and infant feces
using solid phase extraction.[19] Then, HMOs were reduced to
alditols using sodium borohydride[20,21] and were analyzed by
an Accela Ultra High Pressure Liquid Chromatography (UH-
PLC) system (Thermo Scientiﬁc, Waltham, MA, USA), which
was coupled to a Velos Pro mass spectrometer (Thermo Scien-
tiﬁc) with an electrospray ionization probe. A volume of 5 µL
of reduced sample or HMO commercial standard was injected
onto a ThermoHypercarb Porous Graphitic Carbon LC Columns
column (100 × 2.1 mm, 3 µm particle size) with a Hypercarb
guard column (10 × 2.1 mm, 3 µm particle size). The separa-
tion was performed using two eluents: A) 1% v/v ACN in water
with 0.1% v/v formic acid and B) ACN with 0.1% v/v formic acid.
The elution proﬁle was applied as follows: 0–5 min, 3% B; 5–
22 min, 3–20% B; 22–32 min, 20–40% B; 32–33 min, 40–100%
B; 33–43 min, 100% B; 43–44 min, 100–3% B; 44–65 min, 3%
B. In total, 12 neutral HMOs (2′FL, LNT and LNnT, 3FL, DFL,
LNDFHI, LNFPI, LNFPII, LNFPIII, LNFPV, LNH, LNnH) and 5
acidicHMOs (3′SL, 6′SL, LSTa, LSTb, LSTc) weremeasured. Data
processing was done by using XCalibur software (Thermo Scien-
tiﬁc), and peak area as extracted from MS signal was used for
quantitation. Quantitation of 3FL was by high-performance an-
ion exchange chromatography–pulsed amperometric detection
(HPAEC-PAD). The analysis was applied on an ICS 5000 system
(Dionex, Sunnyvale, CA), equippedwith a CarboPac PA-1 column
(250 mm× 2 mm ID) and a CarboPac PA guard column (25 mm
× 2 mm ID) and with a column temperature of 20 °C. The two
mobile phases were A) 0.1 m NaOH and B) 1 m NaOAc in 0.1 m
NaOH.With a ﬂow rate of 0.3mLmin−1, the gradient elution pro-
ﬁle was as follows: 0–10min, 0–10%B; 10–10.1min, 10–100%B;
10.1–15 min, 100% B; 15–15.1 min, 100–0% B; 15.1–30 min, 0%
B. The elution was monitored by a pulsed amperometric detector
(Dionex ICS-5000 ED). Data processing from HPAEC was done
by using Chromeleon 7.1 software (Dionex). The HMOs concen-
trations were measured in micrograms per milliliters of milk or
micrograms per gram of feces.
2.5. Data Analysis
The 16S rRNA gene sequencing data were analyzed using the
NG-Tax analysis pipeline using default settings.[22] In brief, li-
braries were ﬁltered to contain only read pairs with perfectly
matching barcodes that were subsequently used to separate reads
by sample. Operational taxonomic units (OTUs) were assigned
using an open reference approach and SILVA 111 SSU 16S
rRNA gene reference database (https://www.arb-silva.de/).[23] Mi-
crobial composition data were expressed as a relative abundance
of each OTU obtained with NG-Tax.
Infants were classiﬁed into three distinct microbial cluster
types based on genus level microbial abundance data using
Dirichlet Multinomial Mixture (DMM) modeling.[24] Brieﬂy, the
number of Dirichlet components was selected by inspection of
the ﬁt of the model to the count data for varying number of com-
ponents (1 to 7). Goodness of ﬁt was assessed using the Laplace
and the Akaike information criteria. Finally, each sample was as-
signed to the component for which it had the largest ﬁtted value
using the DirichletMultinomial R package[25] in R (version 3.3.1).
Microbial composition of each DMM cluster is shown in Figure
S1, Supporting Information.
Redundancy analysis (RDA) was done in Canoco5[26] using the
log transformed OTU level relative abundance data with signif-
icance assessed using a permutation test. Explanatory variables
included concentrations of milk HMOs: 2′FL, LNT and LNnT,
LNFPIII, LNFPII, LNFPI, LNFPV, LNH, LNnH, LNDFHI, DFL,
6′SL, 3′SL, LSTc, LSTb, LSTa, 3FL, deliverymode (normal vaginal,
assisted vaginal, and C-section), delivery place (home, hospital),
gender, gestational age, mother’s antibiotic use, infant’s signs of
sickness (more speciﬁcally, the signs of gastroenteritis including
vomiting, fever, and diarrhea) at the time of sample collection,
infant age in days, and birth weight. The association between
fecal microbiota composition, the assignment of each infant
to a speciﬁc microbial cluster, and the HMO concentrations
in corresponding breast milk samples of the infant’s mother
were investigated with partial least squares regression (PLS)
using MatlabR2107a, and resulting p-values were corrected for
multiple comparisons using FDR. The Chi-square test was used
to assess the signiﬁcance of the association between infant’s
gender and infant’s microbial cluster type, and betweenmother’s
secretor status (positive, negative) and infant’s microbial cluster
type.
HMO degradation (consumption) in the infant GI tract was
estimated based on proﬁles in breast milk and corresponding in-
fant feces. Based on the utilization of the 17 individual HMOs,
infants were assigned to consumption categories: “Complete,”
“Non-speciﬁc,” and “Speciﬁc” (acidic, neutral, or other). The Chi-
square test was used to assess the signiﬁcance of the association
between the assigned consumption category for each HMO and
the microbial DMM cluster type of each infant.
Based on the extent to which each individual HMO was con-
sumed (calculated as a ratio of theHMO concentration in infants’
feces and the concentration of the same HMO measured in
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Table 1. Average,minimum,maximum, andmedian concentrations of individual HMOs, classes, and total measuredHMOs and corresponding standard
deviations (SD), in breast milk and in infants’ feces solution (1 g feces per 9 mL of peptone glycerol medium).
Concentrations of HMO or HMO category
Maternal breast milk [µg mL−1] Infant fecal solution [µg mL−1]
HMO Min Max Median Average SD Min Max Median Average SD
3FL 5.0 1098.0 182.0 248.0 222.0 NA NA NA NA NA
2′FL 0.0 852.8 460.0 372.7 242.3 0.0 240.3 0.5 29.6 61.4
LNT and LNnT 214.2 1806.7 948.0 976.2 319.0 0.0 372.7 15.8 48.6 75.0
LNFPIII 50.7 758.0 243.9 270.1 140.7 0.0 726.7 0.0 41.0 98.0
LNFPII 0.0 1341.5 236.3 339.0 294.3 0.0 549.0 3.1 81.9 125.5
LNFPI 0.0 1493.7 517.2 467.3 367.5 0.0 505.7 0.0 41.8 91.3
LNFPV 0.0 191.4 27.7 41.8 50.1 0.0 75.0 0.0 2.5 8.7
LNH 0.0 313.0 89.5 105.0 64.1 0.0 161.2 0.0 4.4 17.3
LNnH 0.0 299.1 56.1 72.2 56.3 0.0 563.4 0.4 12.1 57.0
LNDFHI 0.0 1856.2 548.3 475.5 388.3 0.0 889.8 28.0 204.3 258.2
DFL 0.0 125.9 42.1 40.4 32.1 0.0 68.4 0.6 9.7 17.0
6′SL 16.6 385.7 97.3 110.8 63.5 0.0 298.5 0.1 18.4 46.7
3′SL 16.8 194.8 91.5 90.7 38.8 0.0 100.0 0.0 4.2 14.9
LSTc 14.7 334.1 98.8 116.2 68.8 0.0 248.5 0.8 28.9 56.8
LSTb 53.2 804.4 244.4 256.2 118.7 0.0 499.9 1.8 52.2 104.5
LSTa 6.3 83.4 24.6 28.2 15.4 0.0 31.7 0.0 2.1 6.1
Sum neutral 1542.0 5717.3 3064.8 3160.2 824.2 0.0 1671.6 237.9 475.9 523.1
Sum fucosylated 266.5 4489.4 2042.5 2006.8 737.6 0.0 1591.7 186.1 410.8 463.4
Sum sialylated 174.1 1273.2 564.7 602.1 210.6 0.0 956.3 3.3 105.8 197.1
Sum total 1917.4 6545.2 3635.9 3762.3 939.1 0.0 2169.9 267.3 581.7 648.0
For abbreviations and structures of HMOs, please refer to Table S1, Supporting Information; NA, not determined.
mothers’ milk), infants were divided into tertiles (“low,”
“medium,” or “high”) for consumption levels of each individual
HMO. If a given HMO was not detected in milk, the consump-
tion score was not included in the analysis, and if the amount
in feces exceeded the amount detected in milk, the infant was
assigned to the “low” category for that HMO. Associations
between fecal microbiota composition and the assignment
of each infant to a “low,” “medium,” or “high” consumption
category for each HMO were investigated with RDA analysis in
Canoco5, with signiﬁcance assessed using a permutation test.[26]
Kruskal–Wallis analysis was performed in QIIME[27,28] to identify
bacterial OTUs that diﬀered signiﬁcantly between infants who
were classiﬁed as “high,” “medium,” and “low” consumers for
each individual HMO.
2.6. Nucleotide Sequences
KOALA data sets cannot be made publicly available due to data
conﬁdentiality and the potential to identify individual study par-
ticipants from the data. Data are available to the research com-
munity through the Dataverse repository (https://dataverse.nl/;
10411/CEGPGR) upon request to Prof. C. Thijs of the KOALA
Study Management Committee at Department of Epidemiol-
ogy, Maastricht University, PO Box 616, 6200 MD Maastricht,




HMOs in maternal milk and in infant feces were quantiﬁed. The
minimum, maximum, median, average, and standard deviation
of the concentrations of each HMO, the HMO type (neutral, fu-
cosylated, and sialylated), and the total amounts are summarized
in Table 1. Total concentrations of the measured HMOs in milk
ranged from 2.0 to 6.5 mg mL−1 and were lower than those re-
ported in literature.[11,29,30] We observed large individual variation
in the HMO concentrations in both the maternal milk samples
and in infant feces. In most samples, the percentage of neutral
HMOs was higher than that of acidic HMOs (Table 1). The fuco-
sylated HMOs accounted for the vast majority of neutral HMOs.
The composition of fucosylated HMOs in milk depends on the
Lewis and secretor status of a mother, and in some samples, we
did not detect fucosylated HMOs at all. Structures like 2′FL and
LNFP I were present in high concentrations in milk of secre-
tors, while they were absent in non-secretors. Other structures,
like LNFP II, were present as main HMOs in the Lewis-positive
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Figure 1. Constrained analysis (RDA) of diﬀerent factors and milk HMO levels and their association with the fecal OTU proﬁle of infants. Samples are
labeled and enveloped based on the infant assignment to microbial cluster type A, B, or C.
mothers, while they were absent in the Lewis-negative mothers.
We could not detect LNDFH I and DFL in breast milk samples
containing α1-2- and α1-4-fucoses frommothers who were Lewis
or secretor negative. Some neutral HMOs were detected in all
milk samples, that is, 3′FL, LNFP III, LNT, and LNnT. Only one
mother lacked LNH and LNnH in her milk. The acidic HMOs
were detected in all milk samples. These observations were close
to those published before.[19,29] Similar to the HMOs in breast
milk samples, there was also a large variation in HMO concen-
trations in the infant feces. However, the median values of milk
HMO concentration matched well with the average values, while
this was not the case for the HMO levels in feces, indicating a
right-skewed distribution for the fecal proﬁles that was diﬀerent
from the bell-shaped distribution observed for the milk HMO
proﬁles (Table 1).
3.2. Fecal Microbiota Composition and Microbial Clusters
Illumina HiSeq sequencing of the V4 region of bacterial 16S
rRNA genes yielded 14 474 685 high-quality reads that passed
the quality check and could be assigned to 531 OTUs from 113
genera. In case an OTU could not be classiﬁed to a given genus
level, it was assigned to the next available taxonomic rank. The
predominating genera in this infant cohort were Bifidobacterium,
Bacteroides, Escherichia–Shigella, and Parabacteroides, with a
mean relative abundance of 32% (0–91.5%), 21.3% (0–76.7%),
11.8% (0–57.8%), and 6.7% (0–64%), respectively. Genera with
the highest number of contributing OTUs included Bacteroides
(64 OTUs), Bifidobacterium (38 OTUs), Parabacteroides (31
OTUs), Lactobacillus (24 OTUs), and Streptococcus (20 OTUs).
Eighty two OTUs of the total 531 OTUs were found in at least 6
or more infants of the 121 infants studied (Table S3, Supporting
Information). The remaining low prevalence OTUs are found in
ﬁve or fewer infants and are summarized as “Other” (Table S3,
Supporting Information). Overall, the fecal microbiota compo-
sition of infants in this cohort was highly variable, yet we could
distinguish presence of three universal microbial patterns based
on DMM cluster analysis (Figure S1, Supporting Information).
These clusters were characterized by microbial communities
with a mixed structure (Cluster A), or by communities with
either a high relative abundance of Bifidobacterium (Cluster C), or
a high relative abundance of both Bifidobacterium and Bacteroides
(Cluster B).
3.3. The Eﬀect of HMOs in Breast Milk and Other Factors on
Fecal Microbiota Composition
We used RDA to identify factors aﬀecting fecal microbiota
composition of infants in the study (Figure 1). Together, the
explanatory variables explained 21.7% of the variation in the
OTU data. However, only mode of delivery and gender had a
signiﬁcant eﬀect on microbiota composition (p < 0.05), and milk
2′FL concentration was borderline signiﬁcant (p = 0.06). PLS
regression also showed a signiﬁcant association between 2′FL
(and LNFPI) concentrations in milk with infant microbiota (FDR
<0.05, Table S4, Supporting Information). When samples were
color-coded by infant’s DMM cluster type, we also noted that,
based on the RDA vector distribution, high levels of 2′FL and
LNFPI in milk, as well as C-section, were all associated with mi-
crobial cluster A, which was characterized by a mixed microbial
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Figure 2. Diﬀerent utilization patterns of infants deﬁned based on the comparison of HMO proﬁles in breast milk and infant feces. Peak assignments
are as follows: N2-2′FL, N3-LNT, N4-LNnT, N5-LNFP I, N6-LNFP II, N7-LNFP III, N8-LNFP V, N9-DFL, N10-LNDFH I, N11-LNH, N12-LNnH; S1-6′SL,
S2-3′SL, S3-LSTa, S4-LSTb, S5-LSTc.
proﬁle (Figure 1). The association between breast milk HMO
composition and the assignment of each infant to a speciﬁc
microbial cluster type was further investigated using RDA (data
not shown). The results indicated an association between overall
HMO composition in milk and the DMM cluster type (p <
0.05, 3.1% explained). We used Chi-square analysis to test if the
mother’s secretor status (yes/no), which is known to aﬀect the
ability to synthesize (α1-2)-linked fucose, and thus, the amount
of somemajor neutral HMOs inmilk (e.g., 2′FL and LNFPI), had
an eﬀect on infant microbiota proﬁles, as characterized by diﬀer-
ent DMM cluster types, but the association was not signiﬁcant (p
= 0.08) (Table S5, Supporting Information). Also, infant gender
was not signiﬁcantly associated with any of the DMM cluster
types.
3.4. The Association Between Infant Fecal Microbiota
Composition and HMO Degradation
By comparing the HMO proﬁles in breast milk and in corre-
sponding infant feces, we detected the presence of ﬁve patterns
in the HMO consumption (Figure 2). The ﬁrst pattern (“Com-
plete”) was characterized by low or undetectable amounts of any
of theHMOs in infant feces, suggesting a complete consumption
of all HMOs from the breast milk. The second pattern (“Non-
speciﬁc”) showed a fecal HMO proﬁle that was comparable to
that of breast milk and contained high concentrations, thus im-
plying a non-speciﬁc (or broad) and incomplete (or slow) con-
sumption of HMOs by the infant GI tract microbiota. The third
pattern (“Speciﬁc”) indicated selective consumption of speciﬁc
HMOs and was further divided into three types. “Speciﬁc acidic”
showed a high level of neutral HMOs in feces, meaning that the
acidic HMOs (3′SL, 6′SL, LSTa, LSTb, LSTc) were predominantly
utilized. “Speciﬁc neutral” was characterized by the acidic HMO
proﬁle of the feces, meaning that neutral HMOs were predomi-
nantly utilized by the infant GI tract microbiota. The third type
was “Speciﬁc other,” which could not be categorized as neither
acidic nor neutral HMOs (data not shown).
We used RDA analysis to investigate the association between
microbiota composition and diﬀerent HMO consumption pat-
terns. We noted that “Complete,” “Non-speciﬁc,” and “Speciﬁc
acidic” consumptions were signiﬁcantly associated with infant
microbiota composition (FDR <0.05), while the association of
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Figure 3. Association of general HMO consumption patterns with microbial cluster types A, B, C. a) RDA showing the association between HMO
consumption patterns and microbial OTUs. Fifteen best ﬁtting OTUs are displayed and samples are color-coded based on their cluster type assignment;
b) segregation of infants based on their HMO consumption pattern in relation to their microbial cluster type classiﬁcation.
“Speciﬁc neutral” and “Speciﬁc other” was not signiﬁcant. In
addition, “Complete” consumption correlated with high relative
abundance of biﬁdobacteria, including the two highly abundant
Bifidobacterium OTUs 614 and 418 (Figure 3a). Furthermore,
the Chi-square test showed a strong and signiﬁcant association
(χ 2 = 32.28; p < 0.00001) between the frequency of diﬀerent
consumption patterns and each DMM microbial cluster. Forty
percent of infants who were classiﬁed in the mixed microbial
cluster A also showed a non-speciﬁc HMO consumption pattern
(Figure 3b).
In order to investigate the association between microbiota
composition and consumption of speciﬁc HMOs in more depth,
we classiﬁed infants as “low,” “medium,” or “high” consumers
for each of the measured HMOs. We then used this classiﬁca-
tion in the multivariate RDA analysis and showed that the HMO
consumption explained 61.5% of variation inmicrobiota. Infant’s
degradation ability of 2′FL, LNT and LNnT,DFL, 6′SL, LNH, LNF-
PII, LNFPIII (FDR <0.05), LSTb (FDR = 0.06), LSTc, and 3′SL
(FDR = 0.07) was associated with diﬀerences in the fecal mi-
crobiota composition (Figure 4). For all HMO types, there was
a general trend relating consumption eﬃciency and infant fecal
microbiota cluster class. RDA showed that microbial DMM clus-
ter type alone could explain 8.4% of variation in the consump-
tion category and that the cluster eﬀect was statistically signif-
icant (FDR <0.05). The lowest eﬃciency of consumption was
linked to microbial cluster type A, with 40.6% at “high” level,
10% at “medium” level, and 49.4% of all HMOs consumed at
“low” level. Infants classiﬁed in microbial cluster B showed high
HMO consumption levels, with 47.3% of all HMO types con-
sumed at “high” level, 21.3% consumed at “medium” level, and
31.4% at “low” level. Infants classiﬁed in microbial cluster C
showed “high” consumption for 49.8% of all HMOs, “medium”
consumption for 24.4%, and “low” consumption for 25.8%. The
microbial cluster type consumption eﬃciency pattern varied for
diﬀerent HMO types (Figure 5). Chi-square analysis was used to
test the correlation between the proportion of infants in “high,”
“medium,” and “low” consumption categories for each HMO
and the infant microbial cluster groups. Signiﬁcant (p < 0.05)
diﬀerences were detected between clusters with respect to con-
sumption of 2′FL, LNFPIII, LNFPII, DFL, and 6′SL. For the afore-
mentioned HMOs, the highest proportion of infants with the
lowest ability to break down these HMOs was found in cluster
A (Figure 5).
Kruskal–Wallis analysis was used to compare microbiota com-
position at the OTU level between infants who were classiﬁed
as either “high” or “low” consumers for each HMO measured
in this study (Figure 6 and Table S6, Supporting Information).
Infants who showed “high” consumption of 2′FL and DFL had
signiﬁcantly higher relative abundance of OTUs Bifidobacterium
418 and Lactobacillus 744 (FDR < 0.05). In addition, “high” DFL
consumption was associated with signiﬁcantly higher relative
abundance of Bifidobacterium OTUs 406, 643, 423, and 597.
Similarly, infants who showed “high” consumption of LNT and
LNnT, LNFPIII, LNFPII, and LNH had a signiﬁcantly higher
relative abundance of Bifidobacterium OTUs 418, 406, 643, 423,
and 597. Relative abundance of Bifidobacterium 418 was higher in
infants who were eﬃcient degraders of LNnH and LNDFHI, and
Bifidobacterium 416 was associated with degradation of LNFPII,
and Bifidobacterium 614 with LNFPII and LNH. We could not
detect statistically signiﬁcant diﬀerences (with FDR <0.05) in
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Figure 4. RDA showing the association between the degree of degradation of individual HMOs andmicrobial OTUs. OTUs which were signiﬁcantly (p<
0.05) increased in high-degrading infants for at least one of the HMOs are displayed. Taxa with FDR<0.05 are highlighted in bold. For more information
on average relative abundance of the displayed OTUs in the study population and the detailed results of Kruskal–Wallis analyses (see Tables S3 and S6,
Supporting Information). Samples are color-coded based on microbiota cluster type assignment. Red triangles indicate consumption of each HMO, as
summarized in red text.
Figure 5. Proportion of infants showing either “high,” “medium,” or “low” HMO consumption levels, within each microbial cluster class A, B, C.
Signiﬁcant diﬀerences in distribution as determined by Chi-square analysis are indicated with an asterisk.
the relative abundance of taxa between infants characterized as
“high” and “low” degraders of LNFPI, LNFPV, 3′SL, LSTa, LSTb,
and LSTc.
Kruskal–Wallis test comparing infants who were classiﬁed as
“high” and “medium” consumers for diﬀerent HMOs showed
no statistically signiﬁcant diﬀerences in distribution of any
of the OTUs (data not shown). Infants classiﬁed as “low”
and “medium” consumers showed signiﬁcant diﬀerences (FDR
<0.05) in relative abundance of Bifidobacterium 418 for 2′FL and
LNFPII;BifidobacteriumOTUs 418, 643, 406, and 423 forDFL;Bi-
fidobacterium 418 and Bifidobacterium 416 for LNFPIII; Bifidobac-
teriumOTUs 418, 643, 406, 597, and 423 for LNT and LNnT (data
not shown). The observed patterns in the abundance of these taxa
between the “low” and “medium” consumption classes mim-
icked those seen between “low” and “high” consumers for these
HMOs (Table S6, Supporting Information).
4. Discussion
Fecal microbiota composition of healthy, 1-month-old breastfed
infants was characterized in this study using 16S rRNA gene
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Figure 6. OTUs signiﬁcantly associated with HMO consumption based on Kruskal–Wallis test including infants classiﬁed as high and low consumers
for each HMO. Red lines indicate higher OTU relative abundance in relation to low HMO consumption; blue lines indicate higher relative abundance in
relation to high consumption. OTU nodes which are connected with the highest number of HMOs are indicated by darker shades of pink. Dotted lines
indicate associations with p < 0.05; solid lines indicate associations with FDR <0.05.
sequencing and revealed high inter-individual variability in
the fecal microbiota composition. Microbial patterns could be
observed in the sequencing data, and the DMM analysis revealed
that all infants could in fact be classiﬁed into three categories
based on their fecal microbial proﬁles. Even though the high
variability in infant fecal microbiota composition had been
reported,[31] the occurrence of similar microbial clusters had
been described previously in only one study.[32] The origin of
these microbial patterns seen during infancy and their health
implications are still unknown.
Several factors in early life may aﬀect the dynamics of the de-
veloping infant GI microbiota. Our results showed that at about
4 weeks of age, mode of delivery and gender could explain the
observed variation in the microbiota composition. The eﬀect of
mode of delivery has been indicated in infants of similar age in
another study.[33] Also, the eﬀect of gender in infants of that age
had been implied previously using qPCR/RTqPCR analyses for
speciﬁc species/strain detection in feces.[34] Our study shows that
gender-associated diﬀerences can also be detected at the micro-
bial community level in healthy breastfed infants.
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4.1. Breast Milk HMO Levels Have a Limited Eﬀect on Fecal
Microbiota Composition in 1-Month-Old Infants
One of the key factors shaping infantmicrobiota in early life is in-
fant diet. Exclusively breastfed infants show high inter-individual
variability, leading to the question whether these diﬀerences can
be linked to the breast milk properties, including the unique
HMO composition of the milk. It has been estimated that in
healthy breastfed infants most of the ingested HMOs can reach
the colon undigested.[35–37] These HMOs serve as an abundant
and diverse carbon source available for bacterial fermentation.[5]
Using PLS modeling, we could detect statistically signiﬁcant as-
sociations between infant fecal microbiota composition andmilk
LNFPI and 2′FL levels (Table S4, Supporting Information). Both,
LNFPI and 2′FL are neutral, fucosylated, unbranched HMOs
with an α1,2 linkage joining fucose and galactose, and they were
on average the third and fourth most abundant HMO measured
in our dataset. The same association was found in another study
of 3-month-old breastfed infants, albeit using a much smaller co-
hort (n = 16), which further indicated that LNFPI was positively
associated with Bacteroides and Bifidobacterium, and 2′FL with
Bacteroides.[7] Based on our RDA analysis (Figure 1), these two
HMOs were associated with mixed microbiota cluster type A,
which is characterized by low relative abundance of Bacteroides
and Bifidobacterium. In addition, none of the other HMOs
showed signiﬁcant association with microbiota composition,
but based on the vector positions (Figure 1), one could argue
that higher concentrations of a number of diﬀerent HMOs in
maternal milk could be driving the infant microbiota away from
cluster A, but not speciﬁcally towards clusters B or C. Some of
the possible explanations could be that a combined eﬀect of a
number of HMO structures may be necessary to guide micro-
biota development in early life, or that stronger associations
develop over a longer period, and that at 1 month of age the
microbial proﬁle of infants in our study was still largely in its
transitional phase.[38,39] In addition, other HMO structures that
were not measured in our study might also play a role, as well as
the undigested residual lactose from breast milk, which in the
lower intestine could also be readily fermented by the resident
microbiota.
Other breast milk components, such as secretory IgA, lactofer-
rin, lysozyme, as well as the breast milk microbiota itself, are all
likely to contribute to shaping the structure of microbial com-
munities within infants’ GI tracts[2,40–43] and possibly conceal-
ing the eﬀect of the individual HMOs. Over 200 diﬀerent micro-
bial genera had been identiﬁed in human milk to date, of which
Streptococcus and Staphylococcus tend to be the most predomi-
nant taxa.[44–46] Vertical transfer between mother’s breast milk
and infant’s GI tract of viable populations of diﬀerent microbial
groups, including few species and strains of Lactobacillus and Bi-
fidobacterium had also been conﬁrmed and implied as one of the
key factors in establishing infant’s gut microbiota.[46] Breast milk
also contains large amounts of lysozyme, up to 400 µg mL−1,
which acts selectively on diﬀerent microbial species; for exam-
ple, both Bifidobacterium bifidum and Bifidobacterium longum
had been shown to be resistant to lysozyme, whereas clostridia,
and many other Gram-positive and Gram-negative bacteria were
highly susceptible.[43] Thus, the modulatory function of breast
milk likely comes from the synergetic eﬀect of all of its compo-
nents, and HMOs alone might not be the driving factor in shap-
ing the microbiota in early life.
4.2. HMO Consumption Patterns are Associated with Speciﬁc
Microbial Groups
The matched analysis of HMO proﬁles from breast milk and fe-
cal samples allowed us to estimate the in vivo HMO degrada-
tion levels within each infant, and to study in much greater de-
tail the relationship between infant GI microbiota composition
andHMOutilization. Based on this novel approach, we were able
to classify infants into ﬁve HMO consumption groups. A previ-
ous pilot study reported only two types of HMO fecal proﬁles in
infants, namely the neutral and the acidic proﬁles.[47] However,
links between these utilization patterns and the infant fecal mi-
crobiota composition have remained largely unknown. Our data
showed a strong signiﬁcant association between “Non-speciﬁc”
(or low) consumption and themicrobial DMMcluster A, whereas
the “Complete” consumption pattern was related with cluster C
and “Speciﬁc-acidic” with cluster B (Figure 3). Thus, even though
the GI tract microbial ecosystem is still in its early establishment
phase at 1 month of age, we showed that the degradation of dif-
ferent types of HMOs was carried out by speciﬁc bacterial assem-
blages, with evolved mechanisms for eﬃcient consumption of
these abundant food components in milk.
Biﬁdobacteria are the main group of microorganisms in the
lower GI tract of healthy infants, and also the main consumers
of HMOs.[48–50] Our data support this, as the most abundant and
prevalent OTUs detected were of biﬁdobacterial origin (Table
S3, Supporting Information). Earlier in vitro studies showed
highly speciﬁc metabolic behavior of diﬀerent biﬁdobacterial
species and strains with respect to their ability to utilize diﬀerent
HMOs.[6] Themost prevalent OTU in our set was Bifidobacterium
614, with an average relative abundance of 23.3% and prevalence
of 92%. NCBI blast analysis revealed that the OTU sequence
(Table S7, Supporting Information) matched several diﬀerent
species and strains of Bifidobacterium, including various strains
of B. longum (infantis), commonly found in the infant GI tract.
Our analysis showed that Bifidobacterium 614 was associated
with high in vivo consumption of various HMOs, speciﬁcally
2′FL, DFL, LNDFHI, LNFPII, LNFPIII, LNH, and LNT and
LNnT (Table S6, Supporting Information). The second most
abundant OTUwas Bifidobacterium 418, found in 45% of infants,
with an average relative abundance of 6.6%. The NCBI blast
analysis of OTU 418 returned a 100% match to several diﬀerent
strains of B. bifidum (DSM 20456 = ATCC 29521 = JCM 1255,
NBRC100015, KCTC3202). The presence of Bifidobacterium 418
correlated strongly (FDR <0.05) with high consumption levels
of 2′FL, LNT and LNnT, LNFPIII, LNFPII, LNH and its isomer
LNnH, LNDFHI, and DFL, and with LNFPI, LSTa, LSTb, and
LSTc (p < 0.05). B. bifidum has been shown to be an eﬃcient
HMO degrader in in vitro fermentation studies able to secrete
glycosidases to degrade HMOs extracellularly, also making it
possible for other species/subspecies to access the HMO degra-
dation byproducts and metabolites during cross-feeding.[6] In
vitro studies showed that B. bifidum DSM 20456 could eﬃciently
degrade LNT, 2′FL, LNnT, LNFPI, LNFPII, LNFPIII, and
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LNDFHI, though the rate at which it was degrading these
HMOs varied.[6]
Streptococcus and Staphylococcus OTUs showed an increase
in relative abundance speciﬁcally in relation to high consump-
tion of the fucosylated HMOs—DFL, LNFPII, and LNFPIII. Al-
though, in vitro studies showed that Streptococcus and Staphylo-
coccus cannot eﬀectively metabolize HMOs,[51] it has been shown
that the presence of HMOs may enhance growth of breast milk–
associated Staphylococcus by activating growth-promoting signal-
ing andwithout being activelymetabolized by this strain.[51] Strep-
tococcus and Staphylococcus cross-feeding on HMO metabolites
might also play a role, though to date there are no studies docu-
menting it.
Bacteroides and Parabacteroides (formerly also Bacteroides) are
among the ﬁrst dominant bacterial groups, next to biﬁdobacte-
ria, established in the infant GI tract.[52] In general, members of
the genus Bacteroides can degrade a broad range of simple and
complex sugars, oligosaccharides, and polysaccharides, includ-
ing HMOs, mucus glycans, and plant-derived polysaccharides.[3]
Like biﬁdobacteria, Bacteroides spp. can grow on milk glycans
as a sole carbon source; however, biﬁdobacteria might be bet-
ter adapted to utilize a wider range of HMO structures, includ-
ing simple HMO structures, as it has been shown for B. infantis
and LNnT.[52] The trophic niche overlap might explain why in-
fants with high levels of Bifidobacterium, such as those classiﬁed
in the DMM cluster C tend to have lower levels of Bacteroides. On
the other hand, Bacteroides has been shown to eﬃciently degrade
mucus glycans, and because of the similarity of HMO structures
and mucus glycans, some Bacteroides species could also eﬀec-
tively degrade speciﬁc HMOs by activating the mucus-degrading
pathway.[52,53] These species might be better at competing with
biﬁdobacterial groups, especially those species of Bifidobacterium
which might be less adapted for HMO utilization. Our analysis
indicated that infants who were eﬃcient degraders of the sialy-
lated (acidic) HMOs (3′SL, 6′SL, LSTa, LSTb, LSTc) and classiﬁed
into “Speciﬁc acidic” consumption category were also often as-
signed to the Bacteroides dominated DMM cluster B (Figure 2).
This was in agreement with another study which showed that
among others, the HMOs 3′SL and 6′SL could be used as sole
carbon source to support growth of Bacteroides fragilis, Bacteroides
vulgatus, and Bacteroides thetaiotaomicron.[54] Furthermore, these
species, as well as few other species, including certain strains of
B. longum were also shown to metabolize sialic acid.[55]
Finally, a biologically important microbial group commonly
detected in infant feces is the lactobacilli. Our results show that
high levels of degradation of 2′FL, DFL, LNDFHI, LNT and LNnT,
and LNFPII were signiﬁcantly correlated with higher relative
abundance of this group. Remarkably, the opposite eﬀect was
noted for LSTb (Figure 6). Unfortunately, the two interesting lac-
tobacilli OTUs which were identiﬁed in our data, namely Lacto-
bacillus 744 and Lactobacillus 852, had sequence reads which re-
turned a 100% match to more than a dozen species and strains
of lactobacilli in the NCBI blast analysis, making it impossible
to unequivocally identify these populations to the species level.
Several Lactobacillus spp. have been frequently isolated from
neonate feces, including L. fermentum, L. casei, L. paracasei, L. del-
brueckii, L. gasseri, L. rhamnosus, and L. plantarum.[56] These lac-
tobacilli were shown to be unable to eﬃciently ferment HMOs in
vitro[57,58]; however, they have been shown to grow well on HMO
metabolites in vitro.[58] Thus, via the cross-feeding with other bac-
teria, for example, biﬁdobacteria, it is possible that HMO degra-
dation can be linked with higher relative abundance of lacto-
bacilli and other community members in the microbial ecosys-
tem within GI tract.
The roles of diﬀerent HMOs in the development of infant GI
tractmicrobiota, the occurrence ofmicrobial clusters, and the nu-
tritional and health consequences relating to the existence of dif-
ferent trophic networks that are built upon the degradation of
speciﬁc HMOs are still mostly unknown. Our results conﬁrmed
the central role of biﬁdobacteria in theHMObreakdown and pro-
vided an insight into diﬀerent microbial assemblages in healthy,
1-month-old infants. Furthermore, carrying out the analyses at
the OTU level allowed us to uncover a higher level of detail show-
ing that, for example, biﬁdobacteria were associated with both
clusters B and C (17% and 41%, respectively), but the distribu-
tion of speciﬁc biﬁdobacterial OTUs within these two clusters
was not identical (data not shown). Until now, few in vitro studies
demonstrated that closely related species or strains might exhibit
diﬀerent metabolic activities and be involved in a range of com-
plementary trophic interactions. Future studies should strive to
identify the species or strains that are present in the infant gut
and to build understanding on the interactions between these
species. In the future, a better understanding on how the bac-
terial assemblages form in vivo and the identiﬁcation of the key
species and their roles in driving the colonization, as well as their
eﬀects on the host, could be translated into practical applications
within infant nutrition and health.
5. Conclusion
GI tractmicrobiota composition in 1-month-old breastfed infants
is shaped by multiple factors, including HMOs. We observed
a direct link between 2′FL and LNFP I in breast milk and mi-
crobial community composition in this cohort, but it is likely
that the infant microbiota is shaped through the combined ef-
fect of all HMOs and other bioactive components in breast milk.
We showed that breast milk HMO degradation patterns diﬀered
among infants belonging to diﬀerent microbial cluster types.
Degradation of speciﬁc HMOs could be correlated with an in-
crease in relative abundance of various phylotypes (OTUs) within
the genus Bifidobacterium and to a lesser extent within the genera
Bacteroides and Lactobacillus.
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